TD-8236(TD-8236) - 药物靶点：JAK_专利_临床

概要

基本信息

药物类型

小分子化药

别名

TD 8236

靶点

JAK

作用方式

抑制剂

作用机制

JAK抑制剂(Janus 激酶抑制剂)

治疗领域

免疫系统疾病呼吸系统疾病

在研适应症-

非在研适应症

哮喘

原研机构

Theravance Biopharma, Inc.

在研机构-

非在研机构

Theravance Biopharma, Inc.

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 TD-8236 相关的临床试验

NCT04150341

/ Completed临床2期

A Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study to Evaluate the Effects of Repeated Doses of Inhaled TD-8236 and Impact on Airway Responses Following Allergen Challenge in Patients With Asthma

This will be a randomized, double-blind, placebo-controlled study. The study will use a three-period, six-sequence, complete-block, cross-over study design to characterize two doses of inhaled TD-8236 compared to placebo in subjects with mild asthma and a known response to an allergen. Each of the three periods will be 14 days, followed by a washout period before the next period.

开始日期2019-11-06

申办/合作机构

Theravance Biopharma, Inc.

NCT03652038

/ Completed临床1期

A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD-8236 by Inhalation of Single Ascending Doses in Healthy Subjects (Part A) and Multiple Ascending Doses in Subjects With Stable, Mild Asthma (Part B), and Stable, Moderate-to-Severe Asthma (Part C)

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in subjects with stable, mild asthma, and Part C (Biomarker) is a multiple dose study in subjects with stable, moderate-to-severe asthma.

开始日期2018-11-07

申办/合作机构

Theravance Biopharma, Inc.

100 项与 TD-8236 相关的临床结果

登录后查看更多信息

100 项与 TD-8236 相关的转化医学

登录后查看更多信息

100 项与 TD-8236 相关的专利（医药）

登录后查看更多信息

100 项与 TD-8236 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床2期	英国	Theravance Biopharma, Inc.	2019-11-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03652038 (ERS2021) 人工标引	临床1期	轻度哮喘 fractional exhaled nitric oxide (FeNO)	39	TD-8236	餘觸壓簾淵齋蓋選遞觸(襯鑰範築鹽齋廠衊餘蓋) = All adverse events were mild or moderate in severity, and none led to discontinuation of treatment. 蓋蓋壓蓋餘蓋網夢夢膚 (夢鹹餘獵範醖選網艱膚 )	积极	2021-09-05